{"id":688233,"date":"2022-09-22T16:09:59","date_gmt":"2022-09-22T20:09:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/"},"modified":"2022-09-22T16:09:59","modified_gmt":"2022-09-22T20:09:59","slug":"neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/","title":{"rendered":"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PITTSBURGH and CAMBRIDGE, Mass., Sept.  22, 2022  (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology platform company Drugging the Genome\u2122 to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022.<\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td colspan=\"3\">Details of the presentation are as follows:<\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/td>\n<td>Monday,\u00a0October 3rd<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>\u00a0<\/td>\n<td>9:00am \u2013 9:25am ET<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>\u00a0<\/td>\n<td>Fireside Chat<\/td>\n<\/tr>\n<\/table>\n<p>An audio replay of the webcast will be available following the presentation for 90 days. To access the replay, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IoRuBXTvV4dLcoSuCIBUOJkfYneAwhkYryJual8D-B1B_-YdwhGVz70GIwpI7-azQw22RViRm-W2AWu2WuGgTtHPQYCJxR84YPfPL_D3hug-_E3khNK-DOScGxapgTH-xy9Gwj9pPGoAs-VtllemEOaGb9Ke3R-9BsRv8fRY4yQeMU5LrzC3Pn0GpZXtX3wAaciU6z-8jdTvnyeacJ0NnA==\" rel=\"nofollow noopener\" target=\"_blank\">click here<\/a>. Please contact your representative at Chardan to schedule a one-on-one meeting with NeuBase management during the conference. <\/p>\n<p><strong>About NeuBase Therapeutics<\/strong><br \/>NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that Drug the Genome\u2122. The Company\u2019s therapies are built on a proprietary platform called PATrOL\u2122 that encompasses a novel peptide-nucleic acid antisense oligonucleobase technology combined with a novel delivery shuttle that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular, and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions, who currently have limited to no treatment options. To learn more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=P6RcyETmzU_yzPo_ipYEhC3mZ4GyqDtlYKRp-yAOc8hVXagfK25X2IvQcUkr1xTFzPPC2n4VgdHUTbcVc7KHgB9l9KlWEGGOs-7WsvdwprMIVNmRX5VbeNyvTL_hfISN\" rel=\"nofollow noopener\" target=\"_blank\">www.neubasetherapeutics.com<\/a>.<\/p>\n<p>\n        <strong>NeuBase Investor Contact:<\/strong>\u00a0<br \/>Daniel Ferry<br \/>Managing Director\u00a0<br \/>LifeSci Advisors, LLC\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UthnIx-HjUJ_dYXQN7XkTDMvVvWL5HTy6vxHe2KjtK0cumA5yZqER2L6-XX5miDFaREM4ciKhLs-vcZFQzM-8M7bzw8pZLJ_pekuGma1c81hnF5PadscB_bcl4w9vOby\" rel=\"nofollow noopener\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><br \/>OP: (617) 430-7576<\/p>\n<p>\n        <strong>NeuBase Media Contact:<\/strong><br \/>\n        <br \/>Jessica Yingling, Ph.D.<br \/>President<br \/>Little Dog Communications Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pD-yz-1DzgwlhnHFuvxVT8PnvyJ4egFDxGxJ27yXthhZs_dSk3V3TSEgWokhh9J5Wz6RjBFhvpdeCdzA6xRHRGkmk_tmzQ6dFAuFF68uLtE=\" rel=\"nofollow noopener\" target=\"_blank\">jessica@litldog.com<\/a><br \/>OP: (858) 344-8091<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmNlZDkyOGUtYmJiMS00YTQ3LWJhOTYtY2QxMTcxZTc4ZDM4LTUwMDA2NDg3Ng==\/tiny\/NeuBase-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology platform company Drugging the Genome\u2122 to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022. Details of the presentation are as follows: Date: \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 Monday,\u00a0October 3rd Time: \u00a0 9:00am \u2013 9:25am ET Format: \u00a0 Fireside Chat An audio replay of the webcast will be available following the presentation for 90 days. To access the replay, please click here. Please contact your &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688233","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology platform company Drugging the Genome\u2122 to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022. Details of the presentation are as follows: Date: \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 Monday,\u00a0October 3rd Time: \u00a0 9:00am \u2013 9:25am ET Format: \u00a0 Fireside Chat An audio replay of the webcast will be available following the presentation for 90 days. To access the replay, please click here. Please contact your &hellip; Continue reading &quot;NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T20:09:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference\",\"datePublished\":\"2022-09-22T20:09:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/\",\"name\":\"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==\",\"datePublished\":\"2022-09-22T20:09:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/","og_locale":"en_US","og_type":"article","og_title":"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","og_description":"PITTSBURGH and CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) &#8212; NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (\u201cNeuBase\u201d or the \u201cCompany\u201d), a biotechnology platform company Drugging the Genome\u2122 to address disease at the base level using a new class of precision genetic medicines, today announced that company management will participate in-person for a fireside chat at Chardan\u2019s 6th Annual Genetic Medicines Conference being held in New York City on October 3-4, 2022. Details of the presentation are as follows: Date: \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 Monday,\u00a0October 3rd Time: \u00a0 9:00am \u2013 9:25am ET Format: \u00a0 Fireside Chat An audio replay of the webcast will be available following the presentation for 90 days. To access the replay, please click here. Please contact your &hellip; Continue reading \"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T20:09:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference","datePublished":"2022-09-22T20:09:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/","name":"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==","datePublished":"2022-09-22T20:09:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0Nzg0MCM1MTU2MzAxIzUwMDA2NDg3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neubase-to-participate-at-chardans-6th-annual-genetic-medicines-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuBase\u00a0to Participate at Chardan\u2019s 6th Annual Genetic Medicines Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688233","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688233"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688233\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688233"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688233"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}